2024

NOV

13

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a […]

OCT

29

LimmaTech Biologics will be attending the 2024 BARDA Innovation Symposium in Washington on 6 November 2024.

Dr Michael Kowarik to present

OCT

17

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a […]

AUG

01

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive […]

JUL

30

LimmaTech Biologics will be attending the 25th Annual World Vaccine Congress Europe in Barcelona from 28 through 31 October 2024.

Dr Michael Kowarik to present

JUL

01

LimmaTech Appoints Staph Leavenworth Bakali as Chairman of the Board

Schlieren (Zurich), 1 July 2024 – LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of […]

APR

12

LimmaTech Biologics will be attending the Bio€quity Europe 2024 in San Sebastian from 12 through 14 May 2024.

LimmaTech to present

APR

12

LimmaTech Biologics will be attending the Swiss Biotech Day in Basel from 22 through 23 April 2024.

MAR

05

LimmaTech Biologics will be attending the 8th AMR Conference in Basel from 5 through 7 March 2024.

Dr Patricia Martin Killias to present

FEB

27

CARB-X funds LimmaTech Biologics AG to develop a vaccine that prevents gonorrhea infections

The vaccine aims to prevent Neisseria gonorrhoeae infections for which only one antibiotic remains effective in treating resistant bacterial strains.

FEB

22

LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V

Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further […]

FEB

01

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raise to $40 Million

Schlieren (Zurich), February 01, 2024 – LimmaTech Biologics today announced a second closing of its Series A financing, raising an additional USD 3 million from new […]

2023

DEC

19

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

LimmaTech receives an exclusive clinical development license from AbVacc for a multivalent, toxoid vaccine candidate to prevent infections caused by Staphylococcus aureus, the leading cause of […]

OCT

09

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Schlieren (Zurich), October 9, 2023 – LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led […]

SEP

27

LimmaTech Biologics will be attending the 5th ISIDOG Congress in Athens from 19 through 22 October 2023.

SEP

27

LimmaTech Biologics will be attending the 4th Annual Network Meeting 2023 in Birmingham from 18 through 19 October 2023.

SEP

27

LimmaTech Biologics will be attending the 14th International VPM Days in Hannover from 28 through 29 September 2023.

Dr Michael Kowarik to present

SEP

27

LimmaTech Biologics will be attending the World Vaccine Congress Europe in Barcelona from 17 through 19 October 2023.

AUG

09

LimmaTech Biologics will be attending the 23rd International Pathogenic Neisseria Conference in Boston from 24 through 29 September 2023.

AUG

09

LimmaTech Biologics will be attending the Vaccines Europe 2023 in Berlin from 14 through 15 September 2023.

Dr Paula Carranza to present

JUL

20

LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth

LimmaTech has leveraged a novel technology platform to produce a pipeline of vaccines against multi-resistant bacterial infections that present global health threats

JUL

20

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

LimmaTech in-licenses Shigella bioconjugate vaccine from GSK to continue its clinical development; Phase I/II study completion and results are expected in 2023

MAY

31

LimmaTech Biologics will be attending the Bio International Convention in Boston from 5 through 8 June 2023.

MAY

10

LimmaTech Biologics will be attending the Bio€quity Europe 2023 in Dublin from 14 through 16 May 2023.

Dr Patricia Martin to present

MAR

15

LimmaTech Biologics will be attending the Swiss Biotech Day in Basel from 24 through 25 April 2023.

Dr Patricia Martin to present

MAR

15

LimmaTech Biologics will be attending the Swiss Nordic Bio 2023 in Zurich on 30 March 2023.

MAR

15

LimmaTech Biologics will be attending the BIO-Europe Spring in Basel from 20 through 22 March 2023.

JAN

13

LimmaTech Biologics will be attending the Vaccines as tools to combat antimicrobial resistance congress in Birmingham from 27 through 28 February 2023.

Dr Cristina Alaimo to present

JAN

13

LimmaTech Biologics will be attending the World Vaccine Congress in Washington from 3 through 6 April 2023.

2022

Oct

24

LimmaTech Enters Exclusive License and Collaboration Agreement with Griffith University to Expand its Vaccine Technology Platform

SEP

22

LimmaTech Biologics will be attending the 2022 VASE Conference in Washington from 29 November through 1 December 2022.

Dr Patricia Martin to present

SEP

22

LimmaTech Biologics will be attending the Bactivac Annual Network Meeting 2022 in Kilifi, Kenya from 8 through 10 November 2022.

Dr Cristina Alaimo to present

SEP

22

LimmaTech Biologics will be attending the BIO-EUROPE in Leipzig, Germany from 24 through 26 October 2022.

SEP

22

LimmaTech Biologics will be attending the DCVMN Annual General Meeting 2022 in Pune, India from 20 through 22 October 2022.

JUL

13

LimmaTech Biologics will be attending the World Vaccine Congress Europe 2022 in Barcelona from 11 through 14 October 2022.

Dr Michael Kowarik to present

JUL

13

LimmaTech Biologics will be attending the 22nd International Pathogenic Neisseria Conference in Cape Town from 9 through 14 October 2022.

JUL

13

LimmaTech Biologics will be attending the 16th Vaccine Congress in Riva del Garda, Italy from 12 through 14 September 2022.

JUL

13

LimmaTech Biologics will be attending the Biennial Meeting on Microbial Carbohydrates in Naples from 27 through 29 July 2022.

JUN

03

LimmaTech Biologics will be attending the Microbial Glycobiology Conference in Lisbon from 12 through 16 June 2022.

MAY

25

LimmaTech Biologics will be attending virtually at the 12th International Symposium on Pneumococci and Pneumococcal Diseases from 19 through 23 June 2022.

APR

08

LimmaTech Biologics won the pitching contest at the AMR conference in Basel

Dr Laura Yates presented at the AMR Conference in Basel and won the pitching contest.

APR

06

LimmaTech Biologics will be attending the 6th AMR Conference from 7 through 8 April 2022.

Dr Cristina Alaimo and Dr Laura Yates to present

MAR

07

LimmaTech Biologics will be attending the International Congenital CMV Conference from 28 March through 1 April 2022.

2021

NOV

05

LimmaTech Spin-Out GlycoEra AG Raises CHF 45 million

SEP

03

LimmaTech Biologics will be attending the Swiss Biotech Day on 7 September 2021.

JUL

08

LimmaTech Biologics announces the start of a Phase I/II trial of a novel Klebsiella vaccine candidate.

FEB

15

LimmaTech Biologics will be attending the Candida and Candidiasis Online Conference from 21 through 27 March 2021.

JAN

08

GlycoEra AG Announces its Incorporation and Welcomes Ganesh Kaundinya as Inaugural Member of the Board of Directors

2020

SEP

30

GlycoEra a business unit of LimmaTech Biologics will be attending the BIO-EUROPE Digital from 26 through 29 October 2020.

SEP

08

GlycoEra a business unit of LimmaTech Biologics will be attending the 20TH ANNUAL BIOTECH IN EUROPE FORUM from 21 through 24 September 2020.

AUG

19

GlycoEra a business unit of LimmaTech Biologics will be attending the Digital RESI from 14 through 16 September 2020.

AUG

19

GlycoEra a business unit of LimmaTech Biologics will be attending the virtual Antibody Engineering & Therapeutics Europe 2020 from 24 through 27 August 2020.

JUL

01

LimmaTech Biologics AG and University Hospital of Basel Receive Innosuisse Grant

Jun

01

LimmaTech & our CEO Veronica Gambillara Fonck featured in StartUp City Magazine: «An Alternate Way to Generate Therapeutic Proteins»

APR

30

LimmaTech Biologics will be attending the Digital RESI from 8 through 10 June 2020.

FEB

14

LimmaTech Biologics will be attending the RESI Europe in Paris on 23 March 2020.

JAN

29

LimmaTech Biologics will be attending the BIO-Europe Spring in Paris from 23 through 25 March 2020.

JAN

29

LimmaTech Biologics will be attending the 4th AMR Conference in Basel from 11 through 12 March 2020.

JAN

29

LimmaTech Biologics will be attending the Life Science Zurich Impact Conference in Zurich on 3 February 2020.

LimmaTech Biologics to present

JAN

29

LimmaTech Biologics will be attending the LSX World Congress in London from 4 through 5 February 2020.

JAN

29

LimmaTech Biologics will be attending the Keystone Symposia Antibodies as Drugs: From B Cell Biology to New Treatments in Santa Fe from 2 through 6 February 2020.

JAN

29

LimmaTech Biologics will be attending the SWISS NORDIC BIO 2020 Conference in Zurich on 6 February 2020.

LimmaTech Biologics to present

2019

NOV

10

LimmaTech Biologics will be attending the PEGS Europe in Lisbon from 18 through 22 November 2019.

Sep

09

LimmaTech Biologics announces the start of a Phase I/II Shigella trial in Kenya

SEP

05

LimmaTech Biologics will be attending the 19th Annual Biotech in Europe Forum in Basel from 25 through 26 September 2019.

LimmaTech Biologics to present

SEP

02

LimmaTech Biologics will be attending 2019 SFG Annual Meeting in Phoenix from 2 through 5 November 2019.

Dr Manuela Mally to present

Jul

18

LimmaTech Biologics will be attending the Festival of Biologics in Basel from 15 through 17 October 2019.

Jul

17

LimmaTech Biologics will be attending the BioPharm America in Boston from 11 through 12 September 2019.

Dr Michael Kowarik to present

Jul

17

LimmaTech Biologics will be attending the RESI Conference in Boston on 11 September 2019.

May

20

LimmaTech Biologics will be attending the 25th International Symposium on Glycoconjugates in Milano from 25 through 31 August 2019.

May

03

LimmaTech Biologics will be attending the EUROCARB in Leiden from 30 June through 4 July 2019.

Apr

03

LimmaTech Biologics will be attending the ECCMID in Amsterdam from 13 through 16 April 2019.

MAR

01

LimmaTech Biologics will be attending the Bio-Europe Spring Conference in Vienna from 25 through 27 March 2019.

MAR

01

LimmaTech Biologics will be attending the Swiss Biotech Day in Basel on 7 May 2019.

MAR

01

LimmaTech Biologics will be attending the ChinaBio Partnering Forum in Shanghai from 8 through 9 May 2019.

Dr Michael Kowarik to present.

MAR

01

LimmaTech Biologics will be attending the Bio Convention in Philadelphia from 3 through 6 June 2019.

JAN

31

LimmaTech Biologics will be attending the LSX World Congress in London from 5 through 6 February 2019.

JAN

31

LimmaTech Biologics will be attending the HIC/DSP Bioseparation Conference in Interlaken from 18 through 21 February 2019.

JAN

31

LimmaTech Biologics will be attending the 14th Congress of ECCO in Copenhagen from 6 through 9 March 2019.

JAN

31

LimmaTech Biologics will be attending the 2019 Glycobiology Conference in Lucca from 10 through 15 March 2019.

JAN

10

LimmaTech Biologics will be attending the Pep Talk Congress in San Diego from 14 through 18 January 2019.

Dr. Gerald Posch to present.

2018

Nov

12

LimmaTech Biologics will be attending the 6th Drug Discovery Conference in Frankfurt from 29 through 30 November 2018.

OCT

12

LimmaTech Biologics will be attending the PEGS Europe in Lisbon from 12 through 16 November 2018.

OCT

12

LimmaTech Biologics will be attending the Personalized Medicine Conference in Boston from 14 through 15 November 2018.

SEP

20

LimmaTech Biologics will be attending the BIO-Europe in Copenhagen from 5 through 7 November 2018.

SEP

12

LimmaTech Biologics will be attending the World Vaccine Congress Europe in Lisbon from 29 through 31 October 2018.

SEP

12

LimmaTech Biologics will be attending the European Antibody Congress in Basel from 29 through 31 October 2018.

JUN

22

LimmaTech Biologics will be attending the Benzon Symposium 64 in Copenhagen from 27 through 30 August 2018.

Dr. Manuela Mally to present.

APR

20

LimmaTech Biologics will be attending the Antigen-Specific Immune Tolerance Drug Development Summit in Boston from 24 through 26 April 2018.

APR

20

LimmaTech Biologics will be attending the 2018 BIO International Convention in Boston from 4 through 7 June 2018.

APR

20

LimmaTech Biologics will be attending the Swiss Biotech Day in Basel on 3 May 2018.

APR

12

LimmaTech Biologics will be attending the Microbial Glycobiology Conference at the Federation of American Societies for Experimental Biology in Scottsdale from 17 through 22 June 2018.

MAR

29

LimmaTech Biologics will be attending the ISMB 2018 in Chicago from 6 through 10 July 2018.

MAR

22

LimmaTech Biologics will be attending the 11th Annual Proteins & Antibodies Congress in London from 16 through 17 April 2018.

FEB

02

LimmaTech Biologics will be attending the 13th Congress of ECCO in Vienna from 14 through 17 February 2018.

JAN

31

LimmaTech Biologics will be attending the World Vaccine Congress in Washington from 3 through 5 April 2018.

JAN

24

LimmaTech Biologics will be attending the Microbiome Drug Development Summit in Paris from 29 January though 1 February 2018.

JAN

17

LimmaTech Biologics will be attending the Translational Medicine Conference in Zurich on 22 January 2018.

2017

Nov

27

LimmaTech Biologics will be attending the Annual Meeting of the Antibody Society in San Diego from 11 through 15 December 2017.

OCT

25

LimmaTech Biologics will be attending the PEGS Europe in Lisbon from 13 through 17 November 2017.

OCT

11

Award Winning Paper

LimmaTech Biologics is very pleased to announce that the paper on the “Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial” received an award from The Swiss Society for Infectious Diseases in the category “clinical research in infectious diseases”.

We like to thank all the people involved in this achievement.

SEP

29

LimmaTech Biologics will be attending the Immunogenicity & Bioassay Summit in Washington, USA from 23 through 26 October 2017.

SEP

29

LimmaTech Biologics will be attending the Bio Europe in Berlin, Germany from 7 through 9 November 2017.

SEP

25

LimmaTech Biologics will be attending the 2nd Human Challenge Trials Conference in Rockville, USA from 28 through 30 September 2017.

JUN

16

LimmaTech Biologics will be attending the Vaccines for Enteric Diseases in Albufeira, Portugal from 9 through 11 October 2017.

JUN

16

LimmaTech Biologics will be attending the World Vaccine Congress Europe in Barcelona from 10 through 12 October 2017.

Dr Amir Faridmoayer to present.

MAY

03

LimmaTech Biologics will be attending the 19th EUROCARB in Barcelona from 2 through 6 July 2017.

APR

27

LimmaTech Biologics will be attending the 13th Annual Protein Engineering Summit in Boston from 1 through 5 May 2017.

APR

10

LimmaTech Biologics will be attending the 27th European Congress of Clinical Microbiology and Infectious Diseases in Vienna from 22 through 25 April 2017.

FEB

01

LimmaTech Biologics will be attending the World Vaccine Congress in Washington from 10 through 12 April 2017.

JAN

19

LimmaTech Biologics will be attending the Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies (A7) in Snowbird, USA from 22 through 26 January 2017.

2016

Nov

03

LimmaTech Biologics will be attending the European Antibody Congress in Basel from 14 through 16 November 2016.

OCT

31

LimmaTech Biologics will be attending the Sialoglyco in Santa Barbara from 14 through 17 November 2016.

OCT

31

LimmaTech Biologics will be attending the 2016 Society for Glycobiology Annual Meeting in New Orleans from 19 through 22 November 2016.

SEP

16

LimmaTech Biologics will be attending the 7th Baltic Meeting on Microbial Carbohydrates in Rostock from 25 through 27 September 2016.

JUN

15

LimmaTech Biologics will be attending the Glycosylation in the Golgi complex in Vico Equense from 24 through 28 October 2016.

MAY

27

LimmaTech Biologics will be attending the Intelligent Systems for Molecular Biology (ISMB) in Orlando from 8 through 12 July 2016.

MAY

11

LimmaTech Biologics will be attending the Next Generation Protein Therapeutics Summit on Bioconjugation in San Francisco from 13 through 15 June 2016.

Dr. Joerg Schneider to present poster.

MAY

09

LimmaTech Biologics will be attending the FASEB research summer conference on Microbial Glycobiology in West Palm Beach from 12 through 16 June 2016.

Dr. Michael Kowarik to present.

MAY

02

LimmaTech Biologics will be attending the ASM Microbe 2016 in Boston from 16 through 20 June 2016.

Dr. Manuela Mally and Dr. Patricia Martin to present posters.

MAR

31

LimmaTech Biologics will be attending the Canadian Glycomic Symposium in Banff from 18 through 20 May 2016.

MAR

29

LimmaTech Biologics will be attending the 1st International VASE Conference in Washington from 28 through 30 June 2016.

MAR

03

LimmaTech Biologics will be attending the 10th International Symposium on Pneumococci and Pneumococcal Diseases in Glasgow from 26 through 30 June 2016.

FEB

12

LimmaTech Biologics will be attending the Correlates of enteric vaccine-induced protection in Annecy 21 through 23 March 2016.

FEB

01

LimmaTech Biologics will be attending the 10th Annual Bio Innovation Leaders Summit in Berlin on 8 and 9 February 2016.

2015

NOV

06

LimmaTech Biologics will be attending the International Chemical Congress of Pacific Basin Societies in Honolulu from 15 through 20 December 2015.

Dr. Michael Kowarik to present.

OCT

20

LimmaTech Biologics will be attending the SFG 2015 Annual Meeting in San Francisco from 1 through 4 December 2015.

SEP

07

LimmaTech Biologics will be attending the Swiss Biotech Day: Biopharmaceuticals – from Development to Production in Monthey on 15 October 2015.

AUG

28

LimmaTech Biologics AG starts operating

Schlieren, SWITZERLAND – 28 August, 2015 – LimmaTech Biologics AG (“LimmaTech Biologics”) announced today the start of its operations. LimmaTech Biologics is a Swiss limited liability company, with headquarters and research facilities in Schlieren near Zürich, Switzerland.

AUG

18

LimmaTech Biologics will be attending the 23rd International Symposium on Glycoconjugates in Split from 15 through 20 September 2015.

AUG

12

LimmaTech Biologics will be attending the 15th International Conference on Pseudomonas in Washington from 8 through 12 September 2015.

JUL

07

LimmaTech Biologics will be attending the 9th European Congress on Tropical Medicine and International Health in Basel from 6 through 10 September 2015.

JUN

08

GlycoVaxyn will be attending the 2015 NTN Swiss Biotech Innovation Day in Lucerne on 19 August 2015.

MAY

08

GlycoVaxyn will be attending the Vaccines for Enteric Diseases in Edinburgh from 8 through 10 July 2015.

JAN

20

GlycoVaxyn will be attending the Glycobiology Gordon Research Conference in Lucca from 1 through 6 March 2015.

Dr. Sabina Gerber to present.